Correlation of circulating tumor cells with myeloid-derived suppressive cells in the peripheral blood of patients with advanced small cell lung cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Ippokratis Messaritakis

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

I. Messaritakis, A. Koutoulaki, D. Aggouraki, E..K. Vetsika, E. Politaki, S. Apostolaki, V. Georgoulias, A. Kotsakis

Author affiliations

  • Laboratory Of Translational Oncology, School of Medicine, University of Crete, 71110 - Heraklion/GR
More

Resources

Background

The accumulation of Myeloid-derived Suppressor Cells (MDSCs) and the Circulating Tumor Cells (CTCs) have been proposed as negative prognostic biomarkers in several tumors, including SCLC. However, no studies have shown a correlation of the MDSCs with CTCs in SCLC patients. We aimed to investigate the clinical relevance of CTCs and MDSCs in progressing patients with advanced SCLC.

Methods

Peripheral blood was obtained from 32 SCLC patients at the time of progression after 1st line chemotherapy and 31 healthy controls (HC). Immune cells were determined using flow cytometry and CTCs were detected using both the CellSearch System (CS) and immunofluorescence double staining of PBMCs with anti-TTF1 and/or anti-CD56 and anti-CD45 antibodies (IF). The median percentage of patients MDSCs at baseline was used to characterize MDSCs as high or low. For the CTCs detection using the CS and IF, the cut-off values were ≥5 and ≥1 CTCs, respectively.

Results

The percentage of naïve CD4+ T cells was decreased in patients vs NC at baseline. The whole population of MDSCs (CD33+LinHLA-DR−/low), as well as the granulocytic (G)-(CD15+CD14CD33+CD11b+) and the monocytic (M)-MDSCs (CD14+CD15+CD33+CD11b+LinHLA-DR−/low) were significantly increased in patients (p 

Conclusions

We showed an increased frequency of M-MDSCs in the blood of patients with SCLC at relapse exhibiting a positive correlation with CTCs. These observations seem to indicate that some CTCs' subpopulations may be escape and proliferate in patients with active immunosuppressive mechanisms.

Clinical trial identification

-

Legal entity responsible for the study

N/A

Funding

Laboratory of Translational Oncology, School of Medicine, University of Crete

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings